{
    "clinical_study": {
        "@rank": "48500", 
        "arm_group": {
            "arm_group_label": "Xyntha group", 
            "description": "Xyntha will be administered according to physician's discretion."
        }, 
        "brief_summary": {
            "textblock": "This study is to describe the safety and efficacy of Xyntha\u00ae during the usual care setting."
        }, 
        "brief_title": "Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha\u00ae In Subjects With Hemophilia A", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "detailed_description": {
            "textblock": "non probability sample"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients or legally authorized representatives of pediatric patients agree to provide\n             written informed consent form (data privacy statement).\n\n          -  Pediatric and adult patients who have been treated with Xyntha for Hemophilia A from\n             first approved date by KFDA, or who are planned to be newly prescribed Xyntha.\n\n        Exclusion Criteria:\n\n          -  Patients with a known history of hypersensitivity to original or reformulated Xyntha\n             or any component of the product.\n\n          -  Patients with a known history of hypersensitivity to hamster protein.\n\n          -  Patients participating in an interventional trial of any investigational drug or\n             device."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hemophilia A"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790828", 
            "org_study_id": "B1831078"
        }, 
        "intervention": {
            "arm_group_label": "Xyntha group", 
            "description": "Xyntha will be administered according to physician's discretion.", 
            "intervention_name": "Xyntha : coagulation factor IIIV (recombinant)", 
            "intervention_type": "Drug", 
            "other_name": "Xyntha, MOROCTOCOG ALFA"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1831078&StudyName=Post%20Marketing%20Surveillance%20To%20Observe%20Safety%20And%20Efficacy%20Of%20Xyntha%AE%20In%20Subjects%20With%20Hemophilia%20A"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Guro-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "152-834"
                    }, 
                    "name": "Yonsei Rehabilitation Clinic"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-739"
                    }, 
                    "name": "Pusan National Univ. Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "134-727"
                    }, 
                    "name": "Kyung Hee University Hospital at Gangdong"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha\u00ae In Subjects With Hemophilia A", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The clinical nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; outcome and possible causality will be monitored at every visit in this study", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790828"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Efficacy endpoint: annualized bleeding rates (ABRs) and responses to the on-demand treatment with BeneFIX for all bleeds (4-point scale of assessment: excellent, good, moderate, no response)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Ecologic or Community, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}